MyMD Pharmaceuticals Inc./$TNFA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MyMD Pharmaceuticals Inc.
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.
Ticker
$TNFA
Sector
Primary listing
Employees
2
Headquarters
Website
TNFA Metrics
BasicAdvanced
$30m
-
-$6.06
-
-
Price and volume
Market cap
$30m
52-week high
$8.94
52-week low
$0.04
Average daily volume
566k
Financial strength
Current ratio
3.715
Quick ratio
3.521
Profitability
Management effectiveness
Return on assets (TTM)
-19.64%
Return on equity (TTM)
-62.58%
Valuation
Price to book
1.48
Price to tangible book (TTM)
-7.58
Price to free cash flow (TTM)
-0.01
Free cash flow yield (TTM)
-10,204.08%
Free cash flow per share (TTM)
-4.925
Growth
Earnings per share change (TTM)
-54.55%
3-year earnings per share growth (CAGR)
-81.53%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs